×
Home
About
Disclaimer
Privacy
JCS/T2D - We are advocates. We learn. We share. We inform.
Enter Part of Title
Display #
5
10
15
20
25
30
50
100
200
500
All
Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
Eli Lilly's Tirzepatide Shows Promise in Phase 3 Trial for Heart Failure and Obesity
FDA Approves Lilly's Tirzepatide for Obesity
GLP-1 Receptor Agonists: A New Hope for Obstructive Sleep Apnea and Chronic Kidney Disease
Lifestyle Changes and Anti-Obesity Medications: A Complementary Approach
Summary of the Study on Body Size Change and Risk of Type 2 Diabetes and Cardiovascular Disease
The Surprising Mental Health Benefits of GLP-1 Medications for Diabetes and Obesity
Tune H Pers Awarded for Groundbreaking Obesity and Diabetes Research
Understanding and Addressing the Stigma Faced by People with Type 2 Diabetes and Obesity
Unlocking Heart Health: The SELECT Trial Sheds Light on the Cardiovascular Benefits of Semaglutide Beyond Weight Loss
Articles
A Clearer, More Human View of Glucose Patterns
Promising Science Is Not the Same as Proven Medicine
Professor Juleen R. Zierath: Three Decades of Showing How Exercise Changes Metabolism
Wegovy Will Not Go OTC: What the Sources Actually Say
Bridging Data and Healthcare in the Nordics
How Well Do My CGM and BGM Readings Match?
Epigenetic Clues to Heart Risk in Type 2 Diabetes
Could a Gut Bacterium Help Transform Diabetes and Obesity Care?
Why mRNAs Are a Good Option for Vaccines
Why I Took Medical Courses to Strengthen My Data Skills
New Research Reveals the Hidden Complexity of Insulin Resistance
What the 2025 Diabetes Care Updates Mean for You
How an Hour-by-Hour View Transforms Time in Range Insights
Successfully Completed: Diabetes – A Global Challenge
Join the 5K@ADA Virtual Challenge to Promote Diabetes Awareness and Healthy Living
How Tirzepatide is Revolutionizing Type 2 Diabetes Prevention in Overweight and Obese Adults
Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
FDA Issues Alert on Compounded Semaglutide Dosing Errors
Join the 5K@EASD Virtual Challenge to Promote Diabetes Awareness and Healthy Living
Regulatory Hurdles for Awiqli: Approval in Canada and EU, Concerns in the US
News
June 2026
CardioMetabolic Bridge Aims to Move More Research from Lab to Treatment
Novo Nordisk Reports IT Security Incident Involving Some Clinical Trial Data
FDA Clears Dexcom Stelo as First Over-the-Counter CGM for Children
CONNECT Trial Strengthens the Case for CGM in Non-Insulin Type 2 Diabetes
May 2026
Dexcom G8 Promises Smaller Size and Adaptive Accuracy
April 2026
New ACHIEVE-4 Data May Help Address FDA Safety Questions on Lilly’s Foundayo
Novo Nordisk Expands AI Strategy Through New OpenAI Partnership
Top Subjects
Type 2 Diabetes
Novo Nordisk
Obesity Treatment
GLP-1
Wegovy
Semaglutide
Eli Lilly
Tirzepatide
Ozempic
Zepbound
FDA Approval
Diabetes
Diabetes Management
Obesity
Continuous Glucose Monitoring
Orforglipron
Mounjaro
Clinical Trials
Metabolic Health
Obesity Care
Dexcom
CGM
FDA
Weight Loss
Oral Semaglutide
Dexcom G7
Rybelsus
Diabetes Treatment
FDA Clearance
Diabetes Technology
Contact Us
Search
Search
You are here:
Home
JCS/T2D - A Diabetes Journey
